vatalanib has been researched along with Ovarian Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arevalo, JM; Armaiz-Pena, G; Bankson, JA; Cole, SW; Coleman, RL; Felix, E; Gershenson, DM; Han, LY; Jennings, NB; Kamat, AA; Kim, TJ; Kundra, V; Landen, CN; Li, Y; Lin, YG; Lloyd, M; Lopez-Berestein, G; Lu, C; Lutgendorf, SK; Mangala, LS; Merritt, WM; Newman, RA; Ravoori, M; Sanguino, AM; Sood, AK; Takahashi, R; Thaker, PH | 1 |
| Fidler, IJ; Herrera, C; Killion, JJ; Wood, J; Xu, L; Yoneda, J | 1 |
2 other study(ies) available for vatalanib and Ovarian Neoplasms
| Article | Year |
|---|---|
Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma.
Topics: Animals; Carcinoma; Cell Line, Tumor; Disease Models, Animal; Drug Combinations; Enzyme Inhibitors; Female; Humans; Isoproterenol; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Organ Size; Ovarian Neoplasms; Phthalazines; Pyridines; Radiography; Random Allocation; Stress, Psychological; Terbutaline; Transplantation, Heterologous; Tumor Burden; Vascular Endothelial Growth Factor A | 2006 |
Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Ascites; Capillary Permeability; Female; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Ovarian Neoplasms; Phthalazines; Pyridines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Tumor Cells, Cultured | 2000 |